Imagine being terminally ill and being told a drug that could add years to your life would be made available to you - only to then be told you couldn't get it. That's what's happened to breast cancer patients this week. Pharmaceutical company AstraZeneca refusing to allow its drug Faslodex onto the Pharmaceutical Benefits Scheme after it had been approved. The drug costs $1,600 a month. If it was on the PBS, it would go down to $41 and give terminally ill breast cancer patients extra time with t